Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.8.0.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Tc99m tilmanocept royalty revenue $ 16,000    
Grant and other revenue 275,650 $ 580,030  
Revenue 276,445 580,030  
Cost of goods sold 318  
Research and development expenses 998,956 705,274  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,738,385 2,945,644  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,987 76,790  
Loss from operations [3] (2,499,201) (3,147,678)  
Other expense (4,238,761) [4] (1,171,109)  
Net income (loss) (6,737,962) 85,581,025  
Total assets, net of depreciation and amortization 18,322,227   $ 20,781,436
Capital expenditures  
Income tax (expense) benefit 0 1,454,172  
Net income (loss) from continuing operations (6,737,962) (2,864,615)  
Loss from discontinued operations (255,861)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total 88,701,501  
UNITED STATES      
Total assets, net of depreciation and amortization 18,294,844 32,809,415  
Non-US [Member]      
Total assets, net of depreciation and amortization 27,383 116,172  
Diagnostics Segment [Member]      
Grant and other revenue 232,436 571,362  
Revenue 233,231    
Cost of goods sold 318    
Research and development expenses 785,011 413,202  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (552,098) 158,160  
Other expense [4]  
Net income (loss) (552,098) 88,550,546  
Capital expenditures  
Income tax (expense) benefit   (53,254)  
Net income (loss) from continuing operations   104,906  
Loss from discontinued operations   (255,861)  
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total   88,701,501  
Diagnostics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 13,077,979 9,692,007  
Diagnostics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 26,055 115,279  
Therapeutics Segment [Member]      
Grant and other revenue 43,214 8,668  
Revenue 43,214    
Cost of goods sold    
Research and development expenses 213,945 292,072  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 8,607 2,521  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (179,338) (285,925)  
Other expense [4]  
Net income (loss) (179,338) (189,652)  
Capital expenditures  
Income tax (expense) benefit   96,273  
Net income (loss) from continuing operations   (189,652)  
Loss from discontinued operations    
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total    
Therapeutics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 27,228 897  
Therapeutics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization  
Corporate Segment [Member]      
Grant and other revenue  
Revenue    
Cost of goods sold    
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,729,778 2,943,123  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 37,987 76,790  
Loss from operations [3] (1,767,765) (3,019,913)  
Other expense (4,238,761) [4] (1,171,109)  
Net income (loss) (6,006,526) (2,779,869)  
Capital expenditures  
Income tax (expense) benefit   1,411,153  
Net income (loss) from continuing operations   (2,779,869)  
Loss from discontinued operations    
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total    
Corporate Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 5,189,637 23,116,511  
Corporate Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 1,328 893  
Royalty [Member]      
Tc99m tilmanocept royalty revenue 795  
Royalty [Member] | Diagnostics Segment [Member]      
Tc99m tilmanocept royalty revenue 795    
Royalty [Member] | Therapeutics Segment [Member]      
Tc99m tilmanocept royalty revenue    
Royalty [Member] | Corporate Segment [Member]      
Tc99m tilmanocept royalty revenue    
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($37,987 and $76,790 for the three-month periods ended March 31, 2018 and 2017, and $9,745 was included in discontinued operations for the three-month period ended March 31, 2017).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.